OCUP News and Press, Ocuphire Pharma Inc Com From 11/24/21

Shares of Ocuphire Pharm (OCUP +36.2%) have jumped today after H.C. Wainwright initiated the stock with a buy rating and $26 price target (647% upside). Analyst Matthew Caufield writes that the company is benefitting from top-line phase 3 data of Nyxol (phentolamine) in reversing mydrias...

Gainers: Biofrontera (NASDAQ:BFRI) +154%. Longeveron (NASDAQ:LGVN) +79%. Ocuphire Pharma (NASDAQ:OCUP) +36%. Society Pass (NASDAQ:SOPA) +24%. Biofrontera (NASDAQ:BFRA) +23%. Better Therapeutics (NASDAQ:BTTX) +20%. Applied UV (NASDAQ:AUVI) +19%. Standard Lithium (NYSE:SLI) +19%. Blue Star Food...

Gainers: Biofrontera (NASDAQ:BFRI) +109%, Longeveron (NASDAQ:LGVN) +87%, Ocuphire Pharma (NASDAQ:OCUP) +41%, Better Therapeutics (NASDAQ:BTTX) +24%, Reviva Pharmaceuticals (NASDAQ:RVPH) +12%. Losers: Vallon Pharmaceuticals (NASDAQ:VLON) -34%, Pasithea Therap...

Ocuphire Pharma (NASDAQ:OCUP) +74%. Biofrontera (NASDAQ:BFRI) +53%. Engine Gaming and Media (NASDAQ:GAME) +30% on FY results Longeveron (NASDAQ:LGVN) +16%. Inspira Technologies Oxy (NASDAQ:IINN) +15%. Society Pass Incorporated  (NASDAQ:SOPA) +15% on no apparent news Spark Netwo...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re starting the last day of this short holiday week with a dive into the biggest pre-market stock movers for Wednesday! Source: ventdusud / Shutterstock.com News moving shares today...

Ocuphire Pharma (NASDAQ:OCUP) announces that the first subjects have been enrolled in the MIRA-3 Phase 3 pivotal trial evaluating Nyxol Eye Drops in the reversal of pharmacologically-induced mydriasis (dilation of the pupil). Shares down 5.3% premarket at $3.22. Top-line result...

RM Indication Allows for Rapid Recruitment with Top-line Results Expected in Early 2022 Nyxol has the Potential Opportunity to Address Estimated $500M+ Reversal of Dilation Market with No Approved Therapies Today FARMINGTON HILLS, Mich., Nov. 23, 2021 (GLOBE NEWSWIRE) -- O...

Ocuphire Pharma (NASDAQ:OCUP): Q3 GAAP EPS of -$0.25 beats by $0.09. Revenue of $0.49M Press Release For further details see: Ocuphire Pharma EPS beats by $0.09

On Track to Initiate Additional Phase 3 FDA Registration Trials for Nyxol ® Eye Drops in Reversal of Mydriasis (RM) in 4Q21 and Presbyopia in 1H22 Three Clinical Trial Data Readouts Expected in Early 2022 for Nyxol in Night Vision Disturbance, RM, and RM for Ped...

FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022 Ocuphire Uniquely Positioned in Developing Late-Stage Innovative Therapies for Retinal Disease and Presbyopia FARMINGTON HILLS, Mich., Nov...